Daniel Shelly
Chief Business Development Officer PolTREG
Dr. Shelly is the Chief Business Development Officer and member of the Executive Leadership Team for PolTREG S.A. and its US Subsidiary Immuthera. He is responsible for advancing next generation T-regulatory cell therapies for Autoimmune disease including CAR-Tregs, Allogeneic CAR-Tregs, and In-vivo antigen-specific Tregs for T1D, Neuroinflammatory, and Dermatological Autoimmune diseases. Established Immuthera in the US along with licensing of the novel CD6/CTLA4 CAR-Tregs, recruitment of a world class SAB and Board. He is also an adjunct professor in the Master’s in Clinical Drug Development program at the UC College of Pharmacy since 2004 and was awarded the prestigious “Outstanding Adjunct Faculty Award”.
Seminars
- Present on the ability to stimulate T-regulatory-cells and demonstrate that these stimulated Tregs can suppress T-effectors
- Ongoing findings from 86 patient serum samples collected over 12 years
- Update on preclinical data
- In vivo animal data related to a developing delivery system technology
